Brincidofovir fails to improve survival in adenovirus study

Chimerix Inc. (NASDAQ:CMRX) slipped $0.21 to $4.91 on Monday after disclosing with its 1Q16 financial results that brincidofovir ( CMX001) did not meaningfully improve overall survival at week 24 compared to historical controls in the open-label Phase III AdVise study to

Read the full 417 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE